Affomix to Select mAbs for Kalgene Pharma | GenomeWeb

NEW YORK (GenomeWeb News) – Monoclonal antibody company Affomix said today it has signed an agreement with Kalgene Pharmaceuticals to select antibodies with potential diagnostic and therapeutic use in breast cancer.

Under the agreement, Branford, Conn.-based Affomix will use its Y2HExpress technology to generate antibodies against several proprietary targets selected by Kalgene.

Financial terms of the agreement have not been disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.